Quick Facts at a Glance
- Recall Date
- July 9, 2025
- Hazard Level
- HIGH
- Brand
- Boothwyn Pharmacy
- Category
- Health & Personal Care
- Sold At
- Unknown
- Geographic Scope
- 1 states
- At-Risk Groups
- GENERAL, PREGNANT, PETS
What to Do Now
Use this page like a recall checklist: verify the product first, then act on the official remedy.
Immediate steps
- 1Stop using the product until you confirm whether it is included in the recall.
- 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
- 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
- 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.
Check these identifiers
- Brand
- Boothwyn Pharmacy
- Product type
- Semaglutide Injection
- Model numbers
- 03202025@2, 03202025@3 and 03202025@4 BUD 07/18/2025
- Sizes
- 4 mL
- Sold at
- Unknown
- Where affected
- ALL
Recall Timeline
Key dates and source checks for this recall record.
Recall announced
July 9, 2025
Reported by FDA DRUG
September 10, 2025
RecallRadar source check
April 18, 2026
Consumer action
Use the official remedy and keep documentation.
Hazard Information
Subpotent Drug
What You Should Do
Consumers and healthcare providers should stop using this product immediately. Contact Boothwyn Pharmacy LLC or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
About This Product
Semaglutide injections are used to treat type 2 diabetes and obesity under medical supervision. They are typically prescribed by healthcare providers.
Why This Is Dangerous
Subpotent potency may reduce drug effectiveness and clinical outcomes, requiring medical adjustment.
Industry Context
This recall is not described as part of a broader industry pattern in the provided data.
Real-World Impact
Consumers and patients may need alternative therapies or dosage adjustments as advised by clinicians.
Practical Guidance
How to identify if yours is affected
- Compare to FDA recall listing D-0609-2025
- Confirm quantity of 648 vials
- Verify distribution nationwide
Where to find product info
FDA enforcement listing linked in recall notice; Boothwyn Pharmacy customer service
What timeline to expect
Refund or replacement timelines will be set by Boothwyn Pharmacy after recall validation
If the manufacturer is unresponsive
- Escalate to FDA recall contact
- File a consumer complaint with CPSC if applicable for drug recalls in your jurisdiction
- Seek legal advice if substantial losses occur
How to prevent similar issues
- Verify drug potency before dispensing
- Use only medications from licensed pharmacies
- Keep records of lot numbers and expiration dates
- Consult healthcare providers for substitutions if potency concerns arise
Documentation advice
Keep recall notice, purchase documentation, model numbers, communication with pharmacy, and any adverse events.
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Product Details
Product: Semaglutide injection. Strength: 2.5 mg/mL. Volume: 4 mL per vial. Quantity: 648 vials. Brand: Boothwyn Pharmacy. Distribution: U.S. nationwide. Recall date: 2025-07-09. Status: Active.
Reported Incidents
No injuries or incidents are described in the provided data. The status is active with no incident counts specified.
Key Facts
- 2.5 mg/mL strength
- 4 mL per vial
- Class II recall
- U.S. nationwide distribution
Browse More Recalls
Safety Guide
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet Alerts for Health & Personal Care Recalls
Get instant alerts for recalls that affect you. Free forever.